GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (3)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. LB-288-LB-288
    Abstract: Background: Nicotinamide phosphoribosyltransferase (Nampt) catalyzes the first step in the recycling of nicotinamide into NAD. Cancer cells develop dependence on Nampt due to increased energy requirements and the elevated activity of NAD consuming enzymes such as sirtuins and mono and poly(ADP-ribose) polymerases (PARPs). Identification of Nampt as the target of an orphan cytotoxic compound using chemical proteomics spawned a Nampt drug discovery program at Myriad. We have developed a potent and selective inhibitor of Nampt that inhibits the growth of cancer cells in culture and induces tumor regression in a mouse xenograft model. Materials and Methods: In vitro Nampt activity was measured in a coupled biochemical assay based on the production of fluorescent resorufin. Viability was determined by measuring cellular ATP levels at 72 hrs following addition of compound. Nampt cellular activity was assayed by measuring levels of NAD and NAD-dependent poly (ADP)-ribosylation (PAR). Pharmacokinetic studies were conducted in female CD-1 mice. Anti-tumor activity was evaluated in an HCT116 human colon carcinoma xenograft in nu/nu mice. Results: MPI-0486348 inhibited Nampt activity in vitro with an average IC50 value of 40 pM. Depending upon the time of compound exposure, MPI-0486348 showed TC50 values of 180 pM to 20 nM in HCT116 cells. MPI-0486348 treatment also reduced cellular NAD levels and nuclear PAR levels, with IC50 values of 170 pM and 120 pM, respectively. These cellular effects of MPI-0486348 were prevented by coadministration of nicotinic acid, demonstrating on target mechanism of action. In mouse pharmacokinetic studies, absolute oral bioavailability of 47% was determined using 40% Captisol as the vehicle at an oral dose of 10 mg/kg. The same dose in rats gave an absolute oral bioavailability of 46%. Finally, in HCT116 tumor-bearing mice, a single oral dose of MPI-0486348 (50 or 75 mg/kg) resulted in 31% and 67% regression, respectively. Conclusions: MPI-0486348 is an orally bioavailable small molecule inhibitor of Nampt and shows promising preclinical results in a human xenograft model. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-288.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 10, No. 12 ( 2011-12-01), p. 2267-2275
    Abstract: Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached. Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells. Disruption of Mps1 function induces aneuploidy and cell death. We report the identification of MPI-0479605, a potent and selective ATP competitive inhibitor of Mps1. Cells treated with MPI-0479605 undergo aberrant mitosis, resulting in aneuploidy and formation of micronuclei. In cells with wild-type p53, this promotes the induction of a postmitotic checkpoint characterized by the ATM- and RAD3-related-dependent activation of the p53–p21 pathway. In both wild-type and p53 mutant cells lines, there is a growth arrest and inhibition of DNA synthesis. Subsequently, cells undergo mitotic catastrophe and/or an apoptotic response. In xenograft models, MPI-0479605 inhibits tumor growth, suggesting that drugs targeting Mps1 may have utility as novel cancer therapeutics. Mol Cancer Ther; 10(12); 2267–75. ©2011 AACR.
    Type of Medium: Online Resource
    ISSN: 1535-7163 , 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2062135-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 23_Supplement ( 2009-12-01), p. A77-A77
    Abstract: Background: TTK, also known as Mps1, is a dual-specificity kinase that is essential for the proper amphitelic attachment of chromosomes to the mitotic spindle during mitosis and for preventing anaphase progression until the chromosomes are properly attached. We evaluated the effect of MPI-0479605, a potent and selective inhibitor of TTK, on chromosome segregation and cell cycle progression during an unperturbed mitosis and compared it to the effects of an Aurora or PLK kinase inhibitor. Materials and Methods: The TTK, Aurora, and PLK inhibitors used include, MPI-0479605 (TTK IC50 ∼ 4 nM), VX-680 (Aurora IC50 ∼5 nM) and a thiophene benzimidazole (PLK1 and PLK3 IC50 ∼5 nM). For image analysis, cells were fixed and stained with Hoechst dye and anti-β-tubulin and anti-pericentrin antibodies. Images were taken on a BD Pathway high content imaging system. For cell cycle analysis, cells were fixed, stained with propidium iodide and analyzed by FACS. Alternatively, live cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and analyzed by FACS. BrdU incorporation was measured using a FITC BrdU Flow kit (BD Pharmingen). Results: In asynchronously growing cells, treatment with TTK inhibitor caused defects in chromosome congression at the metaphase plate. This resulted in lagging chromosomes during anaphase and a large increase in the percentage of cells with micronuclei during interphase. These micronuclei stained positive for centromeres, suggesting the presence of whole chromosomes. Aurora inhibitor induced the formation of multipolar spindles and caused severe defects in chromosome alignment at the metaphase plate. This resulted in micronuclei formation as well as multi-nucleated cells. The PLK inhibitor caused a monopolar spindle phenotype, consistent with the requirement for PLK1 to facilitate centrosome maturation. In asynchronously growing cells, treatment with TTK inhibitor had no obvious cell cycle arrest phenotype but induced a significant increase in the apoptotic sub-G1 population of cells. If cells were synchronized at the G1/S border and then released into drug, the majority of cells arrested after one cell division in response to inhibitors of all three mitotic kinases. Cells treated with TTK inhibitor were diploid, whereas cells treated with Aurora inhibitor became tetraploid. PLK inhibitor caused a metaphase arrest followed by apoptotic cell death. Finally, cells treated with either TTK or PLK inhibitor, but not Aurora inhibitor, induced a strong caspase response. Conclusions: Inhibitors of TTK, Aurora or PLK produce distinct phenotypic effects on chromosome segregation and cell cycle progression. Inhibition of TTK abrogates the spindle assembly checkpoint during an unperturbed mitosis. This allows anaphase progression in the presence of misattached chromosomes and leads to chromosome segregation defects and aneuploidy. Subsequent activation of a post-mitotic checkpoint in G1 or S phase results in apoptosis. In contrast, an Aurora inhibitor causes defects in mitotic spindle formation, chromosome segregation, and cytokinesis, resulting in tetraploidy. PLK inhibitor causes metaphase arrest followed by mitotic catastrophe. The phenotypic differences demonstrated here provide evidence that TTK inhibition may provide a novel anti-mitotic mechanism for treating cancer. Citation Information: Cancer Res 2009;69(23 Suppl):A77.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...